Latin America

Three regional dynamics stand out in Latin America this quarter. First, the region is increasingly split between formal research jurisdictions and heritage- or enforcement-led jurisdictions, rather than between “open” and “closed” markets. Brazil and, to a lesser degree, Argentina are the clearest examples of places where universities, hospital psychiatry departments and ethics systems can still support investigator-led work. In Brazil, the combination of ANVISA’s controlled-substance framework, exceptional access routes such as compassionate use, and a mature academic literature around ayahuasca and DMT keeps the country at the centre of regional clinical discussion. Argentina’s pipeline is smaller, but Blossom still tracks 8 psychedelic clinical trials connected to the country, with visible signals in Esketamine, 5-MeO-DMT and Psilocybin, which suggests a modest but real translational base rather than purely anecdotal activity. By contrast, Chile and Colombia are more constrained: Chile’s framework remains tightly controlled and research-led, and Colombia’s recent signals are more about INVIMA enforcement than liberalisation, including explicit warnings around psilocybin-labelled products.

Second, the region’s most visible medical pathway is not classic psychedelics but esketamine and ketamine. This matters because it shapes how regulators, hospitals and payers think about psychedelic-adjacent psychiatry. Mexico is the clearest case, where esketamine has public-system formulary recognition even though access still depends on institutional adoption and procurement. Brazil also has an authorised intranasal esketamine route, and Argentina’s ecosystem includes an established framework for specific psychedelic derivatives, especially esketamine. Chile’s clinically relevant pathway is similarly ketamine-based. In regional terms, this means the near-term growth story is less about legalising psilocybin and more about the gradual normalisation of dissociative and rapid-acting antidepressant pathways that can later serve as reference points for more novel compounds.

Third, Latin America’s strongest scientific advantage remains biodiversity and traditional knowledge, but that advantage is translating into very different kinds of outputs in different countries. Peru and Colombia are the clearest examples of ecosystem-first jurisdictions. Peru’s strongest signal is ayahuasca and Amazonian traditional medicine, with research capacity concentrated in ethnobotany, phytochemistry, qualitative clinical work and conservation science. Colombia similarly leans into ethnobotany, mycology and field-based biodiversity studies, which gives it relevance for natural-product discovery and cultural documentation even though Blossom currently tracks no linked country trials. Brazil bridges both worlds better than any neighbour: it has a deep ayahuasca and DMT literature, but also enough clinical infrastructure to support more formal psychiatric studies. That bridge role is important regionally because it creates the possibility of moving from plant-medicine documentation to regulated protocols, something Peru and Colombia have more difficulty doing at scale.

Fourth, the region’s policy signals are converging on caution rather than liberalisation, but not in the same way everywhere. Mexico’s Article 245 and Article 249 framework keeps classical psychedelics in a narrow research category, while Argentina maintains strict prohibition for classic hallucinogens alongside limited medical pathways for specific derivatives. Chile’s legal architecture is likewise permission-based and supervised. Colombia’s recent posture is notably enforcement-heavy, particularly around illegal psilocybin products, while Peru’s picture remains compound-specific and conservative. In other words, the regional pattern is not one of regulatory momentum towards broad access, but of incremental institutional sorting: approved medicine here, controlled research there, traditional-use protections elsewhere. That sorting is visible in the country mix itself, Brazil and Mexico carry the medical weight, Argentina and Chile carry the clinical-governance weight, and Colombia and Peru carry the biodiversity and tradition weight.

Finally, the regional research mix is still heavily shaped by a small number of compounds, especially esketamine, ketamine, ayahuasca and DMT. Blossom’s country pages show that classical psychedelics appear in the region mostly where there is either a controlled clinical pathway or a strong research institution willing to work through it. The result is a thin but coherent regional pipeline, where psychiatric indications such as TRD and MDD cluster around existing clinical medicines, while cultural and biodiversity-linked work keeps classic psychedelics present in the academic conversation without yet producing broad clinical translation.

Over the next 12 to 24 months, Latin America is likely to remain a region of incremental change rather than headline-grabbing regulatory reform. The most plausible gains are operational: more investigator-led studies in Brazil, continued esketamine and ketamine use as the practical psychiatric entry point in Mexico, and small-scale protocol growth in Argentina where institutional and regulatory conditions allow it. Brazil is the country most likely to produce the region’s most relevant data because it combines academic depth, a history of ayahuasca and DMT research, and a clinical system that can support formal studies. If there is a regional readout to watch, it is probably more likely to come from Brazilian or multinational work than from a sudden policy shift.

On the regulatory side, the conservative baseline is likely to hold. Chile, Colombia and Peru are all more likely to tighten guidance, clarify supervision, or strengthen enforcement than to move towards broad psychedelic access. Colombia’s recent posture suggests that any expansion will be channelled through formal research and not consumer markets. Peru may continue to grow in traditional-medicine governance and conservation science, but that should not be mistaken for a pathway to regulated psychedelic prescribing. Mexico may see some operational improvement in research or institutional adoption, especially around compounds such as esketamine, but classical psychedelics will remain tightly controlled unless there is a larger legal change.

For investors and researchers, the regional implication is clear: the strongest near-term opportunities sit in protocol execution, hospital-based psychiatry, and translational work around already-recognised medicines, not in broad commercial access. The region’s longer-term value may come from its biodiversity, Indigenous knowledge, and clinical expertise, but the next 12 to 24 months are more likely to produce a deeper evidence base than a wider market.